business

Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial

MarketWatch · Jun 8, 2026, 8:44 AM · Also reported by 2 other sources

The drugmaker’s shares tumbled in Copenhagen after saying a fifth of users discontinued its weight-loss drug because of gastrointestinal issues.

Read full story on MarketWatch → More top stories

Also covered by

CNBC Weight loss drug maker sinks 25% after new safety data spooks investors Investing.com Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Aggregated and edited by the Scoop newsroom. We surface news from MarketWatch alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial

Also covered by

More in business